You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Medical Devices & Consumables

Global Vpm1002 Tuberculosis Bcg Based Vaccine Market Research Report 2021, Competitive Analysis, Industry Growth Trends And Forecast 2027

As for March 26, 2020

1.Introduce of VPM1002,a Genetically Modified More Effective BCG Vaccine
VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB.Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.
The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.
Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.

2.Research Progress for VPM1002
Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.
The vaccine is currently being tested in a further Phase III study on adult volunteers in India.

3.VPM1002 Vaccine Clinical Experiment for Against Covid-19
Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.
Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.
The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. "These population groups are particularly affected by the current pandemic", says Leander Grode, Managing Director of VPM "and could therefore particularly benefit from a vaccination with VPM1002". If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.
The global VPM1002 (Tuberculosis BCG Based Vaccine) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
In terms of production side, this report researches the VPM1002 (Tuberculosis BCG Based Vaccine) production capacity, value, ex-factory price, growth rate, market share by manufacturers, regions (or countries) and by Type.
In terms of consumption side, this report focuses on the consumption of VPM1002 (Tuberculosis BCG Based Vaccine) by regions (countries) and by Application.
The global VPM1002 (Tuberculosis BCG Based Vaccine) market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global VPM1002 (Tuberculosis BCG Based Vaccine) market. These figures have been provided in terms of both revenue and volume for the period 2016-2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise VPM1002 (Tuberculosis BCG Based Vaccine) markets such as North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc. Key regions covered in the report are U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE
For the period 2016-2027, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global VPM1002 (Tuberculosis BCG Based Vaccine) market. For the period 2016-2021, it provides sales (consumption) analysis and forecast of different regional markets by each application as well as type segment in terms of volume.
The report includes comprehensive company profiling of leading and emerging companies competing in the global VPM1002 (Tuberculosis BCG Based Vaccine) market. It provides a detailed list of players operating at a global level. The players have been listed according to the type of products they offer in the global VPM1002 (Tuberculosis BCG Based Vaccine) market and other factors. As part of the company profiling, the analysts authoring the report has provided the market entry year of each player considered for the research study. The report also offers extensive price, volume sales, and revenue analysis by the manufacturer at the global level for the period 2016-2021.
By Type and Application Segments
The report includes a detailed analysis of leading and type and application segments of the global VPM1002 (Tuberculosis BCG Based Vaccine) market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue sales analysis and forecast of the global VPM1002 (Tuberculosis BCG Based Vaccine) market by each type segment for the period 2016-2027. It also offers volume sales (consumption) analysis and forecast of the global VPM1002 (Tuberculosis BCG Based Vaccine) market by each type segment for the same period. Also, it provides volume sales (consumption) analysis and forecast of the global VPM1002 (Tuberculosis BCG Based Vaccine) market by each application segment for the same period.
This report includes the following manufacturers:
Vakzine Projekt Management (VPM)
Serum Institute of India
Market Segment by Type
0.5ml Package
1ml Package
2ml Package
Market Segment by Application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
Research Methodology
To compile the detailed study of the global VPM1002 (Tuberculosis BCG Based Vaccine) market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the VPM1002 (Tuberculosis BCG Based Vaccine) market. LBI Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the VPM1002 (Tuberculosis BCG Based Vaccine) market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.

1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size Growth Rate by Type
1.2.2 0.5ml Package
1.2.3 1ml Package
1.2.4 2ml Package
1.2.5 Other
1.3 Market Segment by Application
1.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Share by Application (2016 VS 2021 VS 2027)
1.3.2 0-5 Years Old
1.3.3 5-18 Years Old
1.3.4 18-45 Years Old
1.3.5 45-65 Years Old
1.3.6 ≥65 Years Old
1.4 Study Objectives
1.5 Years Considered

2 Market Perspective
2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size (2016-2027)
2.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue (2016-2027)
2.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales (2016-2027)
2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size across Key Geographies Worldwide: 2016 VS 2021 VS 2027
2.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Regions (2016-2021)
2.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Regions (2016-2021)
2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size Forecast by Region
2.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Forecast by Region (2022-2027)
2.3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Forecast by Region (2022-2027)
2.4 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Regions (Countries) Ranking by Market Size
2.5 VPM1002 (Tuberculosis BCG Based Vaccine) Industry Trends
2.5.1 VPM1002 (Tuberculosis BCG Based Vaccine) Market Trends
2.5.2 VPM1002 (Tuberculosis BCG Based Vaccine) Market Drivers
2.5.3 VPM1002 (Tuberculosis BCG Based Vaccine) Market Challenges
2.5.4 VPM1002 (Tuberculosis BCG Based Vaccine) Market Restraints

3 Competitive Landscape by Manufacturers
3.1 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) Manufacturers by Sales (2016-2021)
3.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Manufacturers (2016-2021)
3.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Manufacturers (2016-2021)
3.1.3 Global 5 and 10 Largest Manufacturers by VPM1002 (Tuberculosis BCG Based Vaccine) Sales in 2020
3.2 Global Top Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) by Revenue
3.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Manufacturers (2016-2021)
3.2.2 Top VPM1002 (Tuberculosis BCG Based Vaccine) Manufacturers Covered: Ranking by Revenue
3.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Share by Manufacturers (2016-2021)
3.2.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in VPM1002 (Tuberculosis BCG Based Vaccine) as of 2020)
3.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into VPM1002 (Tuberculosis BCG Based Vaccine) Market
3.7 Key Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type
4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Historic Market Review by Type (2016-2021)
4.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Type (2016-2021)
4.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Type (2016-2021)
4.1.3 VPM1002 (Tuberculosis BCG Based Vaccine) Price by Type (2016-2021)
4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Forecast by Type (2022-2027)
4.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Forecast by Type (2022-2027)
4.2.3 VPM1002 (Tuberculosis BCG Based Vaccine) Price Forecast by Type (2022-2027)

5 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application
5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Historic Market Review by Application (2016-2021)
5.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Market Share by Application (2016-2021)
5.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Market Share by Application (2016-2021)
5.1.3 VPM1002 (Tuberculosis BCG Based Vaccine) Price by Application (2016-2021)
5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) Sales Forecast by Application (2022-2027)
5.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) Revenue Forecast by Application (2022-2027)
5.2.3 VPM1002 (Tuberculosis BCG Based Vaccine) Price Forecast by Application (2022-2027)

6 North America
6.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Breakdown by Company
6.1.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Company (2016-2027)
6.1.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Company (2016-2027)
6.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type (2016-2027)
6.2.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2027)
6.2.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2027)
6.3 North America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application (2016-2027)
6.3.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2027)
6.3.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2027)
6.4 North America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country
6.4.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2016-2027)
6.4.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2016-2027)
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales Breakdown by Company
7.1.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Company (2016-2027)
7.1.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Company (2016-2027)
7.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type (2016-2027)
7.2.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2027)
7.2.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2027)
7.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application (2016-2027)
7.3.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2027)
7.3.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2027)
7.4 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country
7.4.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2016-2027)
7.4.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2016-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales Breakdown by Company
8.1.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Company (2016-2027)
8.1.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Company (2016-2027)
8.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type (2016-2027)
8.2.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2027)
8.2.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2027)
8.3 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application (2016-2027)
8.3.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2027)
8.3.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2027)
8.4 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Regions
8.4.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Regions
8.4.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales Breakdown by Company
9.1.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Company (2016-2027)
9.1.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Company (2016-2027)
9.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type (2016-2027)
9.2.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2027)
9.2.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2027)
9.3 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application (2016-2027)
9.3.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2027)
9.3.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2027)
9.4 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country
9.4.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2016-2027)
9.4.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2016-2027)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales Breakdown by Company
10.1.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Company (2016-2027)
10.1.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Company (2016-2027)
10.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Type (2016-2027)
10.2.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Type (2016-2027)
10.2.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Type (2016-2027)
10.3 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Application (2016-2027)
10.3.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Application (2016-2027)
10.3.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Application (2016-2027)
10.4 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Market Size by Country
10.4.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Sales by Country (2016-2027)
10.4.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) Revenue by Country (2016-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Company Profiles
11.1 Vakzine Projekt Management (VPM)
11.1.1 Vakzine Projekt Management (VPM) Corporation Information
11.1.2 Vakzine Projekt Management (VPM) Overview
11.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.1.4 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) Products and Services
11.1.5 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) SWOT Analysis
11.1.6 Vakzine Projekt Management (VPM) Recent Developments
11.2 Serum Institute of India
11.2.1 Serum Institute of India Corporation Information
11.2.2 Serum Institute of India Overview
11.2.3 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2016-2021)
11.2.4 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) Products and Services
11.2.5 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) SWOT Analysis
11.2.6 Serum Institute of India Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 VPM1002 (Tuberculosis BCG Based Vaccine) Value Chain Analysis
12.2 VPM1002 (Tuberculosis BCG Based Vaccine) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 VPM1002 (Tuberculosis BCG Based Vaccine) Production Mode & Process
12.4 VPM1002 (Tuberculosis BCG Based Vaccine) Sales and Marketing
12.4.1 VPM1002 (Tuberculosis BCG Based Vaccine) Sales Channels
12.4.2 VPM1002 (Tuberculosis BCG Based Vaccine) Distributors
12.5 VPM1002 (Tuberculosis BCG Based Vaccine) Customers
13 Research Findings and Conclusion

14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
  • PUBLISHED DATE: Apr, 2021
  • NO OF PAGES: 130